Goldman Sachs Projects US Economy to Outperform at 2.5% Growth, Beating Wall Street Consensus
Goldman Sachs raises US GDP forecast to 2.5% for 2026, above the 2.1% consensus, as tax cuts from the One Big Beautiful Bill Act offset tariff headwinds.
TRENDING TOPICS
3055 articles found for "investing"
Goldman Sachs raises US GDP forecast to 2.5% for 2026, above the 2.1% consensus, as tax cuts from the One Big Beautiful Bill Act offset tariff headwinds.
Taiwan secures the best tariff deal among US trade partners at 15%, while TSMC commits to building four more Arizona fabs in historic agreement.
Netflix amends its Warner Bros. Discovery acquisition to an all-cash transaction at $27.75 per share, fending off Paramount Skydance's hostile bid as the deal heads toward shareholder vote.
P&G reports stronger-than-expected Q2 earnings of $1.88 per share despite facing $1 billion in tariff costs, while announcing 7,000 job cuts to streamline operations.
BOJ maintains rates at 0.75%, the highest since 1995, while upgrading growth forecasts and hinting at future tightening as the yen slides toward 160 against the dollar.
President Trump files $5 billion lawsuit against JPMorgan Chase and CEO Jamie Dimon, alleging the bank closed his accounts for political reasons after January 6.
The IMF raised its 2026 global growth forecast to 3.3%, citing technology investment and supportive policies. But the fund warned US inflation will return to target more gradually than expected.
SEC Chair Paul Atkins promised an 'innovation exemption' for crypto entrepreneurs within a month. The policy could transform how digital assets reach American markets.
Lockheed Martin reports Q4 earnings Thursday with a record $179 billion order backlog, as Trump's proposed $1.5 trillion defense budget provides a powerful growth catalyst.
President Trump warns of 100% tariffs on Canadian imports after Canada negotiates a trade deal lowering tariffs on Chinese electric vehicles, escalating North American trade tensions.
Novo Nordisk's oral Wegovy is now available at 70,000 U.S. pharmacies for $149-$299 per month. With Eli Lilly's competing pill expected by mid-2026, the obesity drug market is entering a new era.
The S&P 500 fell 0.5% this week while the Dow lost 0.6%, marking the first consecutive weekly declines since June. Intel's 17% plunge and Goldman's retreat weighed on sentiment ahead of a pivotal week.